PL3986878T3 - Sposób wytwarzania inhibitorów kanału chlorkowego clc-1 - Google Patents
Sposób wytwarzania inhibitorów kanału chlorkowego clc-1Info
- Publication number
- PL3986878T3 PL3986878T3 PL20734157.9T PL20734157T PL3986878T3 PL 3986878 T3 PL3986878 T3 PL 3986878T3 PL 20734157 T PL20734157 T PL 20734157T PL 3986878 T3 PL3986878 T3 PL 3986878T3
- Authority
- PL
- Poland
- Prior art keywords
- clc
- preparation
- chloride channel
- channel inhibitors
- inhibitors
- Prior art date
Links
- 108010062745 Chloride Channels Proteins 0.000 title 1
- 102000011045 Chloride Channels Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19181262 | 2019-06-19 | ||
| PCT/EP2020/067065 WO2020254554A1 (en) | 2019-06-19 | 2020-06-19 | Process for the preparation of clc-1 chloride channel inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3986878T3 true PL3986878T3 (pl) | 2025-01-20 |
Family
ID=66999603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20734157.9T PL3986878T3 (pl) | 2019-06-19 | 2020-06-19 | Sposób wytwarzania inhibitorów kanału chlorkowego clc-1 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12221425B2 (https=) |
| EP (1) | EP3986878B1 (https=) |
| JP (1) | JP7595945B2 (https=) |
| KR (1) | KR102900834B1 (https=) |
| CN (1) | CN113993852B (https=) |
| AR (1) | AR119198A1 (https=) |
| AU (1) | AU2020298092B2 (https=) |
| BR (1) | BR112021025588A2 (https=) |
| CA (1) | CA3137672A1 (https=) |
| ES (1) | ES3000437T3 (https=) |
| HU (1) | HUE069104T2 (https=) |
| IL (1) | IL287901B2 (https=) |
| MX (1) | MX2021013507A (https=) |
| PL (1) | PL3986878T3 (https=) |
| SG (1) | SG11202111122RA (https=) |
| TW (1) | TWI849152B (https=) |
| WO (1) | WO2020254554A1 (https=) |
| ZA (1) | ZA202107653B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4593829A1 (en) | 2022-09-30 | 2025-08-06 | NMD Pharma A/S | Compositions and methods for treating myasthenia gravis |
| WO2024180199A1 (en) | 2023-03-02 | 2024-09-06 | Nmd Pharma A/S | Compositions and methods for treating charcot–marie–tooth disease |
| JP2026508357A (ja) | 2023-03-02 | 2026-03-10 | エヌエムディー ファーマ エー／エス | 脊髄性筋萎縮症を処置するための組成物及び方法 |
| EP4731200A1 (en) | 2023-06-20 | 2026-04-29 | NMD Pharma A/S | Clc-1 inhibitors for use in the treatment of multiple sclerosis and neuromuscular diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0301010D0 (sv) * | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| GB0422057D0 (en) * | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
| GB0524428D0 (en) * | 2005-11-30 | 2006-01-11 | 7Tm Pharma As | Medicinal use of receptor ligands |
| WO2009097970A1 (de) * | 2008-02-05 | 2009-08-13 | Sanofi-Aventis | Triazolopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel |
| JP2015505560A (ja) * | 2012-02-03 | 2015-02-23 | ゾエティス・エルエルシー | 抗寄生虫薬としてのキラルイソオキサゾリンアゼチジン誘導体の製造法 |
| MX389242B (es) | 2015-06-15 | 2025-03-20 | Nmd Pharma As | Compuestos para su uso en el tratamiento de trastornos neuromusculares |
| US10385028B2 (en) * | 2017-12-14 | 2019-08-20 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| TWI780281B (zh) | 2017-12-14 | 2022-10-11 | 丹麥商Ｎｍｄ藥品公司 | 用於治療神經肌肉病症的化合物 |
-
2020
- 2020-06-19 BR BR112021025588A patent/BR112021025588A2/pt unknown
- 2020-06-19 IL IL287901A patent/IL287901B2/en unknown
- 2020-06-19 ES ES20734157T patent/ES3000437T3/es active Active
- 2020-06-19 SG SG11202111122RA patent/SG11202111122RA/en unknown
- 2020-06-19 EP EP20734157.9A patent/EP3986878B1/en active Active
- 2020-06-19 CN CN202080043796.2A patent/CN113993852B/zh active Active
- 2020-06-19 HU HUE20734157A patent/HUE069104T2/hu unknown
- 2020-06-19 TW TW109120910A patent/TWI849152B/zh active
- 2020-06-19 US US17/619,312 patent/US12221425B2/en active Active
- 2020-06-19 JP JP2021569300A patent/JP7595945B2/ja active Active
- 2020-06-19 MX MX2021013507A patent/MX2021013507A/es unknown
- 2020-06-19 CA CA3137672A patent/CA3137672A1/en active Pending
- 2020-06-19 AR ARP200101735A patent/AR119198A1/es unknown
- 2020-06-19 AU AU2020298092A patent/AU2020298092B2/en active Active
- 2020-06-19 KR KR1020217037880A patent/KR102900834B1/ko active Active
- 2020-06-19 WO PCT/EP2020/067065 patent/WO2020254554A1/en not_active Ceased
- 2020-06-19 PL PL20734157.9T patent/PL3986878T3/pl unknown
-
2021
- 2021-10-11 ZA ZA2021/07653A patent/ZA202107653B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3986878A1 (en) | 2022-04-27 |
| HUE069104T2 (hu) | 2025-02-28 |
| BR112021025588A2 (pt) | 2022-02-01 |
| IL287901A (en) | 2022-01-01 |
| EP3986878C0 (en) | 2024-09-25 |
| CN113993852A (zh) | 2022-01-28 |
| TWI849152B (zh) | 2024-07-21 |
| US12221425B2 (en) | 2025-02-11 |
| KR102900834B1 (ko) | 2025-12-16 |
| AU2020298092A1 (en) | 2021-11-18 |
| CN113993852B (zh) | 2024-12-17 |
| SG11202111122RA (en) | 2021-11-29 |
| MX2021013507A (es) | 2021-12-10 |
| TW202115003A (zh) | 2021-04-16 |
| AU2020298092A8 (en) | 2025-04-24 |
| IL287901B2 (en) | 2025-02-01 |
| CA3137672A1 (en) | 2020-12-24 |
| WO2020254554A1 (en) | 2020-12-24 |
| ES3000437T3 (en) | 2025-02-28 |
| JP2022537493A (ja) | 2022-08-26 |
| JP7595945B2 (ja) | 2024-12-09 |
| IL287901B1 (en) | 2024-10-01 |
| AU2020298092B2 (en) | 2025-09-25 |
| ZA202107653B (en) | 2023-05-31 |
| EP3986878B1 (en) | 2024-09-25 |
| KR20220022895A (ko) | 2022-02-28 |
| AR119198A1 (es) | 2021-12-01 |
| US20220298124A1 (en) | 2022-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE061482T2 (hu) | Szintézismódszer | |
| IL276917A (en) | A process for the preparation of alubixivet | |
| IL287901A (en) | A process for making clc-1 chloride channel inhibitors | |
| ZA202101837B (en) | Method for the preparation of synthesis gas | |
| IL289904B1 (en) | Process for preparing biphenylamines | |
| SG11202102204PA (en) | Process of making calcium alpha-ketoglutarate | |
| LT3765440T (lt) | N-alkil-nitratoetilnitraminų gamybos būdas | |
| IL276483B1 (en) | A continuous process for the preparation of trazodone | |
| IL291221A (en) | Methods for the synthesis of wolbenzine | |
| IL283885A (en) | cxcr7 inhibitors for cancer therapy | |
| IL281254A (en) | A process for the preparation of lanbatinib | |
| IL290181B2 (en) | Process for preparing fluonesulfone | |
| ZA202002116B (en) | Process for the preparation of piperine | |
| GB201903055D0 (en) | Method of oligonucleaotide synthesis | |
| PL3599256T3 (pl) | Sposób wytwarzania poliorganosiloksanów | |
| IL277578A (en) | New salt forms of URAT-1 inhibitors | |
| IL279410A (en) | Process for preparing Quinmark | |
| GB201910665D0 (en) | Novel form of compounds | |
| SG11202101817UA (en) | Methods of inhibition | |
| PT3759082T (pt) | Processo para a síntese de 6-clorometiluracilo | |
| PL3774752T3 (pl) | Sposób wytwarzania glicydolu | |
| IL263336B (en) | Compounds for the treatment of symphysiolysis | |
| HUP1800278A2 (en) | Process for the preparation of boc-linagliptin | |
| GB201917499D0 (en) | Methods of synthesis | |
| GB201916150D0 (en) | Treatment of multiple myeloma |